Personalized immunotherapy for ovarian cancer: a new roadmap
A new review led by Prof. George Coukos, published in Nature Reviews Clinical Oncology, proposes a personalized approach for ovarian cancer immunotherapy based on CD8+ T cell immunophenotyping, offering new hope for innovative tailored treatments.
Despite clear evidence that ovarian cancer is an immunogenic disease, immune checkpoint inhibitors (ICIs) have shown limited success so far. Considerable effort is still needed to develop more effective immunotherapy strategies, establish reliable biomarkers, and improve outcomes for patients. This review*, led by Prof. George Coukos and co-authors Dr. Eleonora Ghisoni and Dr. Matteo Morotti, presents a roadmap for personalized immunotherapy treatments based on the immunophenotyping of ovarian cancer.
Read the full <<review>> in Nature Reviews Clinical Oncology.
The systematic classification of ovarian cancer immunophenotypesbased on CD8+ T cell infiltration, combined with genetic information, could offer a practical and rational biomarker to select ovarian cancer patients more effectively for next-generation immunotherapy combinations. The authors also emphasize the importance of modulating the tumor microenvironment and discuss the emerging treatment strategies including adoptive T cell therapy. Clinical trials need to be coupled with translational research efforts to understand responses to immunotherapy and establish the groundwork for further development of rational clinical approaches for patients with ovarian cancer.
This review is a step forward in improving clinical strategies for ovarian cancer, particularly for patients who do not currently respond well to immunotherapies.
*Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
by carine Dournes Söhnlein (DO communication)